| GENENTECH |
GENENTECH |
92%
|
Revenues are comprised of royalty revenues related to Genentech and Roche's net sales of Erivedge ® |
| ROCHE |
ROCHE |
90%
|
Revenues are comprised of royalty revenues related to Genentech and Roche's net sales of Erivedge ® |
| TPC-INVESTMENTS-ROYALTY-LLC |
TPC-INVESTMENTS-ROYALTY-LLC |
90%
|
In November 2025, the Company sold Erivedge to TPC Investments Royalty LLC, a limited liability company managed by Oberland Capital Management, LLC, in exchange for upfront consideration of $2.5 million. |
| BPTH |
Bio-Path Holdings, Inc. |
72%
|
to the processing of personal data that takes place in the UK and includes parallel obligations to those set forth by GDPR. In relation to data transfers, both the UK and the EU have determined, thro… |
| BPTH |
Bio-Path Holdings, Inc. |
72%
|
Reciprocal relationship from BPTH graph: Reciprocal relationship from CRIS graph: Reciprocal relationship from BPTH graph: Reciprocal relationship from CRIS graph: to the processing of personal data … |
| GILD |
Gilead Sciences, Inc. |
72%
|
to the processing of personal data that takes place in the UK and includes parallel obligations to those set forth by GDPR. In relation to data transfers, both the UK and the EU have determined, thro… |
| GILD |
Gilead Sciences, Inc. |
72%
|
Reciprocal relationship from GILD graph: Reciprocal relationship from CRIS graph: to the processing of personal data that takes place in the UK and includes parallel obligations to those set forth by… |
| JNJ |
Johnson & Johnson |
72%
|
to the processing of personal data that takes place in the UK and includes parallel obligations to those set forth by GDPR. In relation to data transfers, both the UK and the EU have determined, thro… |
| JNJ |
Johnson & Johnson |
72%
|
Reciprocal relationship from JNJ graph: Reciprocal relationship from CRIS graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from CRIS graph: to the processing of personal data th… |
| LLY |
Eli Lilly and Company |
72%
|
Reciprocal relationship from LLY graph: Reciprocal relationship from CRIS graph: Reciprocal relationship from LLY graph: Reciprocal relationship from CRIS graph: Reciprocal relationship from LLY grap… |
| LLY |
Eli Lilly and Company |
72%
|
to the processing of personal data that takes place in the UK and includes parallel obligations to those set forth by GDPR. In relation to data transfers, both the UK and the EU have determined, thro… |
| NRIX |
Nurix Therapeutics, Inc. |
72%
|
Reciprocal relationship from NRIX graph: Reciprocal relationship from CRIS graph: to the processing of personal data that takes place in the UK and includes parallel obligations to those set forth by… |
| NRIX |
Nurix Therapeutics, Inc. |
72%
|
to the processing of personal data that takes place in the UK and includes parallel obligations to those set forth by GDPR. In relation to data transfers, both the UK and the EU have determined, thro… |
| RIGL |
Rigel Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from RIGL graph: Reciprocal relationship from CRIS graph: to the processing of personal data that takes place in the UK and includes parallel obligations to those set forth by… |
| RIGL |
Rigel Pharmaceuticals, Inc. |
72%
|
to the processing of personal data that takes place in the UK and includes parallel obligations to those set forth by GDPR. In relation to data transfers, both the UK and the EU have determined, thro… |
| STTK |
Shattuck Labs, Inc. |
72%
|
Reciprocal relationship from STTK graph: Reciprocal relationship from CRIS graph: Reciprocal relationship from STTK graph: Reciprocal relationship from CRIS graph: to the processing of personal data … |
| STTK |
Shattuck Labs, Inc. |
72%
|
to the processing of personal data that takes place in the UK and includes parallel obligations to those set forth by GDPR. In relation to data transfers, both the UK and the EU have determined, thro… |
| VINC |
Vincerx Pharma, Inc. |
72%
|
Reciprocal relationship from VINC graph: Reciprocal relationship from CRIS graph: Reciprocal relationship from VINC graph: Reciprocal relationship from CRIS graph: Reciprocal relationship from VINC g… |
| VINC |
Vincerx Pharma, Inc. |
72%
|
to the processing of personal data that takes place in the UK and includes parallel obligations to those set forth by GDPR. In relation to data transfers, both the UK and the EU have determined, thro… |
| AURIGENE-DISCOVERY-TECHNOLOGIES-LIMITED |
AURIGENE-DISCOVERY-TECHNOLOGIES-LIMITED |
62%
|
er in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical au… |
| CHEVRON-U-S-A-INC |
CHEVRON-U-S-A-INC |
62%
|
ing. Any unanticipated disruption to our contract manufacturing caused by problems at suppliers could delay shipment of our drug candidate, increase our cost of goods sold and result in lost sales wi… |
| CORNER-POST-INC |
CORNER-POST-INC |
62%
|
ing. Any unanticipated disruption to our contract manufacturing caused by problems at suppliers could delay shipment of our drug candidate, increase our cost of goods sold and result in lost sales wi… |
| DELAWARE-GENERAL-CORPORATION |
DELAWARE-GENERAL-CORPORATION |
62%
|
quirements and subject us to liability if we are not in compliance with applicable laws. Our product candidates are subject to export control and import laws and regulations, including the U.S. Expor… |
| F-HOFFMANN-LA-ROCHE-LTD |
F-HOFFMANN-LA-ROCHE-LTD |
62%
|
The Company's operations are located entirely within the U.S. The Company's focus is primarily on the development of emavusertib, a small molecule IRK4/FLT3 inhibitor. The Company was party to a coll… |
| LA-ROCHE-LTD |
LA-ROCHE-LTD |
62%
|
La Roche Ltd (“Roche”) are commercializing Erivedge® (vismodegib), a first-in-class orally administered small molecule Hedgehog signaling pathway antagonist approved for the treatment of advanced bas… |
| NATURAL-RESOURCES-DEFENSE-COUNCIL-INC |
NATURAL-RESOURCES-DEFENSE-COUNCIL-INC |
62%
|
ing. Any unanticipated disruption to our contract manufacturing caused by problems at suppliers could delay shipment of our drug candidate, increase our cost of goods sold and result in lost sales wi… |
| OBERLAND-CAPITAL-MANAGEMENT-LLC |
OBERLAND-CAPITAL-MANAGEMENT-LLC |
62%
|
ensed its proprietary Hedgehog pathway antagonist technologies to Genentech for human therapeutic use. The primary focus of the collaborative research plan has been to develop molecules that inhibit … |
| ROCHE-GROUP |
ROCHE-GROUP |
62%
|
The Company's operations are located entirely within the U.S. The Company's focus is primarily on the development of emavusertib, a small molecule IRK4/FLT3 inhibitor. The Company was party to a coll… |
